Top Page
Cynata Therapeutics Limited
(Sydney:CYP)
Cynata Therapeutics Limited (CYP) vs. iShares MSCI Australia ETF (EWA)
Cynata Therapeutics Limited Business Overview & Revenue Model
Cynata Therapeutics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.89M | 1.89M | 2.32M | 1.65M | 7.77M | 1.55M |
| Gross Profit | 1.89M | 1.89M | 2.32M | 1.37M | 7.49M | 1.27M |
| EBITDA | -9.33M | -9.33M | -9.95M | -15.65M | -6.00M | -8.80M |
| Net Income | -9.39M | -9.39M | -9.74M | -14.28M | -5.45M | -7.69M |
Balance Sheet | ||||||
| Total Assets | 7.20M | 7.20M | 8.39M | 18.99M | 26.55M | 29.97M |
| Cash, Cash Equivalents and Short-Term Investments | 5.05M | 5.05M | 6.21M | 16.17M | 23.80M | 26.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.22M | 1.22M | 1.17M | 2.26M | 2.59M | 1.60M |
| Stockholders Equity | 5.98M | 5.98M | 7.22M | 16.73M | 23.96M | 28.37M |
Cash Flow | ||||||
| Free Cash Flow | -8.72M | -8.77M | -9.96M | -14.28M | -3.30M | -5.16M |
| Operating Cash Flow | -8.72M | -8.72M | -9.96M | -14.28M | -3.30M | -5.16M |
| Investing Cash Flow | -50.00K | -50.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 7.61M | 7.61M | 0.00 | 6.72M | 210.12K | 18.20M |
Cynata Therapeutics Limited Technical Analysis
Cynata Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$79.92M | -8.35 | -49.72% | ― | ― | 10.78% | |
48 Neutral | AU$142.77M | -16.46 | -41.51% | ― | -40.74% | -21.21% | |
46 Neutral | AU$81.92M | -7.08 | -138.54% | ― | ― | 16.61% | |
44 Neutral | AU$33.06M | -9.09 | -143.71% | ― | 306.88% | ― | |
42 Neutral | AU$23.38M | -4.61 | -157.93% | ― | ― | -36.89% | |
40 Underperform | AU$46.37M | -6.80 | -159.86% | ― | 110.44% | 35.90% |
Cynata Therapeutics Limited Corporate Events
Cynata Therapeutics reported strong clinical and operational progress in the December 2025 quarter, highlighted by completion of final patient visits in its large Phase 3 SCUlpTOR osteoarthritis trial of CYP-004 and completion of patient enrolment in its Phase 2 trial of CYP-001 for newly diagnosed high-risk acute graft versus host disease, with efficacy results from both studies expected in the second quarter of 2026. The company also advanced its Phase 1/2 NEREID kidney transplantation study, where an independent safety board cleared the first cohort treated with CYP-001 with no rejection episodes or safety issues, allowing progression to a second cohort with higher dosing; combined with an estimated available cash position of about $3.8 million and a runway into mid-2026, ongoing regulatory engagement and partnering discussions position Cynata for multiple near-term clinical and strategic catalysts that could influence future approval pathways and commercialisation prospects for its Cymerus™ platform.
The most recent analyst rating on (AU:CYP) stock is a Hold with a A$0.30 price target. To see the full list of analyst forecasts on Cynata Therapeutics Limited stock, see the AU:CYP Stock Forecast page.
Cynata Therapeutics has raised approximately $1.2 million in net proceeds via its At-The-Market Subscription Agreement with Acuity Capital, achieved through the set-off of 4.3 million previously issued shares at a deemed price of $0.28, an 11.1% discount to the last traded price. The funds will be used for working capital, strengthening Cynata’s financial position as it advances multiple Cymerus™-based cell therapy clinical programs and supports ongoing development in a competitive regenerative medicine sector.
The most recent analyst rating on (AU:CYP) stock is a Hold with a A$0.30 price target. To see the full list of analyst forecasts on Cynata Therapeutics Limited stock, see the AU:CYP Stock Forecast page.
Cynata Therapeutics has completed patient enrollment in its Phase 2 clinical trial of CYP-001 for treating acute graft versus host disease (aGvHD), a serious complication of bone marrow transplantation. The trial enrolled 65 participants across the US, Europe, and Australia, and aims to address the unmet need for effective aGvHD treatments, as current steroid treatments often fail. The primary evaluation period will conclude in March 2026, with results expected by June 2026. CYP-001 has shown promise in previous trials, with high response rates and no serious safety concerns, positioning Cynata as a potential leader in aGvHD treatment.
Cynata Therapeutics announced a positive review by an independent Data and Safety Monitoring Board (DSMB) for the first cohort in their Phase 1/2 kidney transplant trial using CYP-001, a Cymerus™ MSC therapy. The trial, managed by Leiden University Medical Centre, aims to establish CYP-001 as a safer alternative to current anti-rejection drugs, which have significant toxicity. The DSMB found no safety concerns, allowing the trial to proceed to the next cohort, potentially positioning Cynata as a leader in safer kidney transplantation therapies.
Cynata Therapeutics Limited announced a change in the director’s interest, specifically regarding Dr. Paul K Wotton’s securities. The change involves the expiry of 300,000 unlisted options exercisable at $0.97, resulting in Dr. Wotton now holding 220,000 unlisted options and 585,076 ordinary shares. This update reflects the company’s ongoing management of its securities and may influence stakeholder perceptions regarding director engagement and investment strategies.
Cynata Therapeutics Limited announced a change in the director’s interest, specifically regarding Dr. Darryl Maher’s holdings. On November 29, 2025, 300,000 unlisted options exercisable at $0.97 expired, leaving Dr. Maher with 116,666 ordinary shares and 220,000 unlisted options exercisable at $0.185. This change reflects the expiration of certain options, which may impact the director’s future financial interests in the company.
Cynata Therapeutics Limited announced a change in the interests of its director, Dr. Geoffrey Brooke, with the expiration of 2,000,000 unlisted options exercisable at $0.97 on November 29, 2025. This change reflects a reduction in Dr. Brooke’s holdings, which may impact the company’s stock dynamics and investor perceptions, although the overall strategic direction of the company remains unaffected.
Cynata Therapeutics Limited announced the completion of the final patient visit in its Phase 3 SCUlpTOR trial for CYP-004, targeting osteoarthritis of the knee. This milestone marks the end of a two-year follow-up period, with data analysis expected to conclude by Q2 2026. The trial, conducted in partnership with the University of Sydney, aims to assess whether CYP-004 can modify the disease and alleviate symptoms. Osteoarthritis represents a significant market opportunity, affecting 600 million people globally, and Cynata’s product could offer a less invasive alternative to current treatments.
Cynata Therapeutics Limited has released an updated investor presentation, highlighting its ongoing clinical trials and advancements in cell therapy. The company’s Cymerus™ platform continues to demonstrate potential in treating various diseases, positioning Cynata as a significant player in the regenerative medicine industry. The release of this presentation aims to keep shareholders and interested parties informed about the company’s progress and strategic direction.
Cynata Therapeutics Limited held its Annual General Meeting where all resolutions, including a special resolution for a 10% Placement Facility, were passed. This outcome supports the company’s strategic initiatives and may enhance its financial flexibility, potentially impacting its market positioning and stakeholder interests positively.
Cynata Therapeutics Limited announced an investor webinar hosted by CEO Dr. Kilian Kelly, aimed at providing updates on the company’s activities and key projects. The webinar reflects Cynata’s commitment to engaging with shareholders and stakeholders, offering insights into its ongoing clinical trials and the potential impact of its Cymerus™ technology on the regenerative medicine industry.
Cynata Therapeutics Limited announced it received a $1.7 million R&D Tax Incentive Refund for the 2024/2025 financial year. This refund will support the advancement of Cynata’s cell therapy product pipeline, enhancing its research and development efforts. The Australian Government’s R&D Tax Incentive program encourages companies to engage in innovative activities, such as the development of Cynata’s Cymerus™ MSC products, by providing tax offsets. This financial boost is expected to positively impact Cynata’s operations and industry positioning by enabling further investment in its advanced therapeutic offerings.
Cynata Therapeutics Limited is poised for a significant period with upcoming results from two major clinical trials expected within the financial year. The Phase 2 trial for acute Graft versus Host Disease and the Phase 3 trial for Osteoarthritis are nearing completion, with results anticipated in Q2 CY 2026. These trials are crucial for demonstrating the clinical potential and scalability of Cynata’s Cymerus™ platform. The company is also advancing its Phase 1/2 kidney transplant trial and has secured a financial runway through mid-CY 2026. Cynata’s strategic positioning is strengthened by regulatory trends favoring advanced therapies, potentially accelerating approval processes.